RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Science 37 Holdings Stock

Science 37 Holdings Revenue 2024

Science 37 Holdings Revenue

64.07 M USD

Ticker

SNCE

ISIN

US8086441081

In 2024, Science 37 Holdings's sales reached 64.07 M USD, a 7.62% difference from the 59.53 M USD sales recorded in the previous year.

The Science 37 Holdings Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2027e138.7111,44
2026e107.5214,76
2025e76.6820,70
2024e64.0724,77
2023e59.5326,66
202270.1522,62
202159.628,86
202023.74,68
201923.74,68

Science 37 Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Science 37 Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Science 37 Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Science 37 Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Science 37 Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Science 37 Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Science 37 Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Science 37 Holdings’s growth potential.

Science 37 Holdings Revenue, EBIT and net profit per share

DateScience 37 Holdings RevenueScience 37 Holdings EBITScience 37 Holdings Net Income
2027e138.71 M undefined14.28 M undefined0 undefined
2026e107.52 M undefined2.43 M undefined0 undefined
2025e76.68 M undefined-21.33 M undefined-398.25 M undefined
2024e64.07 M undefined-21.16 M undefined-411.64 M undefined
2023e59.53 M undefined-33.77 M undefined-684.45 M undefined
202270.15 M undefined-105.32 M undefined-50.99 M undefined
202159.6 M undefined-63.72 M undefined-94.33 M undefined
202023.7 M undefined-31.69 M undefined-31.67 M undefined
201923.7 M undefined-31.69 M undefined-31.67 M undefined

Science 37 Holdings stock margins

The Science 37 Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Science 37 Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Science 37 Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Science 37 Holdings's sales revenue. A higher gross margin percentage indicates that the Science 37 Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Science 37 Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Science 37 Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Science 37 Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Science 37 Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Science 37 Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Science 37 Holdings Margin History

Science 37 Holdings Gross marginScience 37 Holdings Profit marginScience 37 Holdings EBIT marginScience 37 Holdings Profit margin
2027e22.62 %10.29 %0 %
2026e22.62 %2.26 %0 %
2025e22.62 %-27.82 %-519.38 %
2024e22.62 %-33.02 %-642.52 %
2023e22.62 %-56.72 %-1,149.7 %
202222.62 %-150.14 %-72.69 %
202128.86 %-106.91 %-158.27 %
20204.68 %-133.71 %-133.63 %
20194.68 %-133.71 %-133.63 %

Science 37 Holdings Aktienanalyse

What does Science 37 Holdings do?

Science 37 Holdings Inc. is a company specializing in clinical trials supported by technology and digital methods. It was founded in 2014 by a team of experienced medical and technological experts. The company is headquartered in Los Angeles, California, USA. Science 37's business model focuses on accelerating clinical trials and reducing costs by facilitating access to patients and data through a digital, telemedicine-based infrastructure. This is changing the way clinical trials are conducted by addressing one of the biggest obstacles to industrial development: the lengthy recruitment of patients. The various divisions of Science 37 include a platform for telemedicine studies, which allows virtual researchers to assess and connect with patients remotely, an in-house platform for clinical data management and analysis, and an extensive network of physicians and patients who offer and participate in clinical studies. Science 37's partners include pharmaceutical companies, biotech companies, academic institutions, and government agencies. Science 37 offers a wide range of products tailored to the specific needs of its customers. These products include: 1. NORA - A telemedicine platform for near-site recruitment, which allows patients to conveniently participate in a clinical trial through their own device. The platform provides a seamless and integrated experience for the patient and facilitates collaboration between study centers and virtual researchers. 2. NEST - A platform for clinical studies designed for the management of large data-driven studies. NEST provides a central database that simplifies the collection and management of study data and complies with compliance requirements. 3. SIV - A cloud-based platform for site initiation visits, which allows sponsors to accelerate study initiation with a wealth of site information without the need for an on-site visit. 4. Decentralized Clinical Trials - A fully digital platform that supports a clinical study from recruitment to data analysis and uses the "bring your own device" paradigm (BYOD). Decentralized Clinical Trials allow access from anywhere, whenever the patient desires. The company has an impressive track record, having worked on more than 27 clinical trials and being awarded numerous accolades, including "Most Innovative Clinical Trial Solution Provider" at the Global Health & Pharma (GHP) Awards 2019. Overall, Science 37 is an innovative company that has revolutionized the way clinical trials are conducted. Technology has the potential to radically transform medical research and accelerate drug development. Science 37 is pushing the boundaries of what is possible in large-scale patient recruitment and is a key player in the digital transformation of clinical research. Science 37 Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Science 37 Holdings's Sales Figures

The sales figures of Science 37 Holdings originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Science 37 Holdings’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Science 37 Holdings's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Science 37 Holdings’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Science 37 Holdings stock

How much revenue did Science 37 Holdings generate this year?

Science 37 Holdings has achieved a revenue of 64.07 M USD this year.

How much was the turnover of the company Science 37 Holdings compared to the previous year?

The revenue of Science 37 Holdings has increased by 7.62% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Science 37 Holdings?

The revenue of Science 37 Holdings is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Science 37 Holdings measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Science 37 Holdings so important for investors?

The revenue of Science 37 Holdings is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Science 37 Holdings pay?

Over the past 12 months, Science 37 Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Science 37 Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Science 37 Holdings?

The current dividend yield of Science 37 Holdings is .

When does Science 37 Holdings pay dividends?

Science 37 Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Science 37 Holdings?

Science 37 Holdings paid dividends every year for the past 0 years.

What is the dividend of Science 37 Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Science 37 Holdings located?

Science 37 Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Science 37 Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Science 37 Holdings from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Science 37 Holdings pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Science 37 Holdings in the year 2023?

In the year 2023, Science 37 Holdings distributed 0 USD as dividends.

In which currency does Science 37 Holdings pay out the dividend?

The dividends of Science 37 Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Science 37 Holdings

Our stock analysis for Science 37 Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Science 37 Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.